Rain Oncology Inc.
rainoncology.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 9, 2023. Its latest SEC filing is a SC 13G/A from Feb 14, 2024.
10-Q for Q3 FY2023, filed Nov 9, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops precision oncology drugs, including milademetan, for patients with cancers selected by tumor genetics.
10-K for FY2022, filed Mar 9, 2023We are a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients we believe…View ↗
Our lead product candidate, milademetan (also known as RAIN-32) is an oral, small molecule inhibitor of the p53-mouse double minute 2…View ↗
Our approach leverages currently available tumor genetic testing strategies to enroll and treat patients with advanced cancer. We employ…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Mar 9, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 9, 2023
−$7MView ↗
- ▼ −61% (Loss)
- vs −$18M in Q3 FY2022
-
Jan 26, 2024
Pathos AI acquired Rain Oncology
Rain became a wholly owned subsidiary after the merger; shareholders received $1.16 in cash per share plus a contingent value right.
Sources
8-K, filed Jan 26, 2024
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on January 26, 2024, Merger Sub completed a…View ↗
-
Dec 14, 2023
Rain agreed to be acquired by Pathos AI
The agreement offered $1.16 in cash per share plus a contingent value right for potential additional payments.
Sources
8-K, filed Dec 14, 2023
On December 13, 2023, Rain Oncology Inc. (the “Company” or “Rain”) entered into an Agreement and Plan of Merger (the “Merger Agreement”)…View ↗
-
May 22, 2023
MANTRA trial missed its primary endpoint
Rain said it did not expect to pursue further development of milademetan for dedifferentiated liposarcoma.
Sources
8-K, filed May 22, 2023
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care –View ↗
Who Did They Compete With?
Competes with Kartos Therapeutics, Ascentage Pharma, Boehringer Ingelheim, and Kymera
10-K for FY2022, filed Mar 9, 2023With respect to our lead product candidate, milademetan, there are no approved drugs targeting MDM2. There are multiple companies testing…View ↗
Loading...
